The field of covalent biologics has made headway recently, as the only biotech in the space has bagged $100 million to move its pipeline to the clinic.
BTK inhibitors were first approved over a decade ago to treat a rare blood cancer. Now, they are in the running to treat a host of autoimmune diseases.